On January 31, 2013, Xia, Guangxin; Shen, Jingkang; Yu, Yongping; Chen, Wenteng; Zhang, Chunchun; Hao, Yu; Zhang, Jing; Li, Bojun; Liu, Xuejun published a patent.Synthetic Route of 1620510-51-1 The title of the patent was Quinazoline derivatives as protein tyrosine kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. And the patent contained the following:
Disclosed are quinazoline derivatives of formula I and their pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, and prodrugs. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivatives, and an application thereof. The quinazoline derivatives of the invention are provided with improved anti-tumor activity. Compounds of formula I wherein R1 is (un)substituted C6-10 aryl, (un)substituted C3-12heteroaryl; R2 is H, halo, OH, amino, C1-6 (halo)alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.; X is halo; R3 and R4 are independently H, C1-6 alkyl, R6R7N-(CH2)1-3-, R6R7N-(CH2)1-2-Y-(CH2)0-4- and Het-W-(CH2)0-2-; R6 and R7 are independently H, C1-6 alkyl, Het-W-(CH2)0-2- and R8-W-(CH2)0-4-; R8 is H, and C1-6 alkyl; Y is O, S and NH and derivatives; Z is NH and derivatives and O; W is NH and derivatives, O and a single bond; Het is 3- to 6-membered heterocyclic ring and 5-membered nitrogen-containing heteroaryl; and their pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, and prodrugs thereof, are claimed. Compounds of formula I were prepared by using condensation and Wittig olefination as the key steps. All the invention compounds were evaluated for their protein tyrosine kinase inhibitory activity. From the assay, it was determined that example compound II exhibited the IC50 value of 1.3, 75 and 23 nM against EGFR, HER2 and HER4, resp. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).Synthetic Route of 1620510-51-1
The Article related to quinazoline preparation protein tyrosine kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 1620510-51-1
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts